Childhood cataract gene discovered

Article

Swiss researchers have identified the defect in the coding region of the gene responsible for childhood cataract by assessing family members who suffered from autosomal dominant juvenile cataract, according to a study published in the March 2008 issue of the American Journal of Human Genetics.

Swiss researchers have identified the defect in the coding region of the gene responsible for childhood cataract by assessing family members who suffered from autosomal dominant juvenile cataract, according to a study published in the March 2008 issue of the American Journal of Human Genetics.

According to the research team, headed by Barbara Kloeckener-Gruissem of the Institute of Medical Genetics, University Zurich, Switzerland, SLC16A12, a mutation in the carboxylic acid transporter family gene SLC16, could provide a connection between juvenile cataract with microcornea and renal glucosuria.

The researchers identified the nonsense mutation by studying members of a large family with autosomal dominant juvenile cataract, microcornea, and renal glucosuria, and found tissue-specific variability of SLC16A12 transcript levels in control samples, with high expression in the eye and kidney.

SLC16A12 is important for lens and kidney homeostasis, and may lead to renal glucosuria, a non-pathological kidney defect defined by elevated glucose level in the urine without hyperglycemia and without evidence of morphological renal anomalies. Poor homeostasis within the lens leads to alterations of the lens structure, resulting in opacity and leading to cataract.

The researchers concluded that SLC16A12 interferes with homeostasis in the lens, and is biologically relevant as a cause of juvenile cataract. Age-related cataract patients are also being screened for mutations in this gene. The investigators believe that understanding the exact function of SLC16 may open new avenues for non-surgical treatment of cataract.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.